share_log

Exact Sciences | 10-Q: Q2 2024 Earnings Report

Exact Sciences | 10-Q: Q2 2024 Earnings Report

精密科学 | 10-Q：2024财年二季报
美股SEC公告 ·  2024/07/31 16:11

Moomoo AI 已提取核心信息

Exact Sciences reported strong Q2 2024 financial results with revenue increasing 12.4% to $699.3 million, driven by 14.9% growth in Screening revenue to $531.6 million and 6.7% growth in Precision Oncology revenue to $167.7 million. The company completed over 1 million Cologuard tests in the quarter for the first time, while operating loss narrowed significantly to $26.3 million from $76.9 million year-over-year.The company continued advancing its product pipeline, with the FDA reviewing the Cologuard Plus premarket approval application and expected to make a decision in late 2024. Exact Sciences also presented promising data from its ASCEND-2 study for multi-cancer screening at AACR and secured an exclusive license to TwinStrand's cell-free nucleic acid sequencing technology for $45 million.Cash and investments totaled $946.8 million as of June 30, 2024. The company issued $620.7 million of 1.75% convertible notes due 2031, receiving net proceeds of $259.8 million. Operating cash flow was $24.8 million for the first half of 2024, with management expressing confidence in funding current operations for at least the next twelve months.
Exact Sciences reported strong Q2 2024 financial results with revenue increasing 12.4% to $699.3 million, driven by 14.9% growth in Screening revenue to $531.6 million and 6.7% growth in Precision Oncology revenue to $167.7 million. The company completed over 1 million Cologuard tests in the quarter for the first time, while operating loss narrowed significantly to $26.3 million from $76.9 million year-over-year.The company continued advancing its product pipeline, with the FDA reviewing the Cologuard Plus premarket approval application and expected to make a decision in late 2024. Exact Sciences also presented promising data from its ASCEND-2 study for multi-cancer screening at AACR and secured an exclusive license to TwinStrand's cell-free nucleic acid sequencing technology for $45 million.Cash and investments totaled $946.8 million as of June 30, 2024. The company issued $620.7 million of 1.75% convertible notes due 2031, receiving net proceeds of $259.8 million. Operating cash flow was $24.8 million for the first half of 2024, with management expressing confidence in funding current operations for at least the next twelve months.
精密科学报告了2024年第二季度强劲的财务业绩，营业收入同比增长12.4%，达到69930万，主要得益于筛查营业收入增长14.9%，达53160万，以及精准肿瘤学营业收入增长6.7%，达到16770万。该公司在本季度首次完成超过100万次的Cologuard测试，同时运营亏损大幅收窄至2630万，较去年同期的7690万有显著改善。公司持续推进其产品管道，FDA正在审查Cologuard Plus的上市前批准申请，预计将在2024年底做出决定。精密科学还在AACR会议上展示了其ASCEND-2多癌症筛查研究的有前景的数据，并以4500万获得TwinStrand的无细胞核酸测序科技的独家许可。截至2024年6月30日，公司现金及投资总额为94680万。该公司发行了62070万的1.75%可转换债券，至2031年到期，获得净收益25980万。2024年上半年运营现金流为2480万，管理层对未来至少12个月的当前运营资金表达了信恳智能。
精密科学报告了2024年第二季度强劲的财务业绩，营业收入同比增长12.4%，达到69930万，主要得益于筛查营业收入增长14.9%，达53160万，以及精准肿瘤学营业收入增长6.7%，达到16770万。该公司在本季度首次完成超过100万次的Cologuard测试，同时运营亏损大幅收窄至2630万，较去年同期的7690万有显著改善。公司持续推进其产品管道，FDA正在审查Cologuard Plus的上市前批准申请，预计将在2024年底做出决定。精密科学还在AACR会议上展示了其ASCEND-2多癌症筛查研究的有前景的数据，并以4500万获得TwinStrand的无细胞核酸测序科技的独家许可。截至2024年6月30日，公司现金及投资总额为94680万。该公司发行了62070万的1.75%可转换债券，至2031年到期，获得净收益25980万。2024年上半年运营现金流为2480万，管理层对未来至少12个月的当前运营资金表达了信恳智能。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    燃石医学
    BNR
    -- 6.940
    Neuronetics
    STIM
    -- 4.360
    Personalis
    PSNL
    -- 5.510
    OncoCyte
    OCX
    -- 2.5600
    恩佐生化
    ENZ
    -- 0.545
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。